peterschreiber.media
Cantor Fitzgerald has initiated protection of Janux Therapeutics (NASDAQ:JANX) with an chubby score, citing the corporate’s management place within the bispecific T-cell engager subject.
The funding agency additionally known as Janux well-capitalized, with round $345M on the finish of This fall plus an roughly $300M fairness increase in February.
“As a frontrunner on this rising and now extremely compelling TCE house, we see large alternative forward for JANX – the potential for a number of best-in-class blockbuster merchandise, profitable partnerships, and certain a big diploma of strategic curiosity,” the analysts wrote of their word.
Cantor set a worth goal of $100 for the inventory.
